Genfit S.A. (GNFT) - Total Assets
Based on the latest financial reports, Genfit S.A. (GNFT) holds total assets worth $216.68 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genfit S.A. - Total Assets Trend (2004–2024)
This chart illustrates how Genfit S.A.'s total assets have evolved over time, based on quarterly financial data. Also see Genfit S.A. (GNFT) total market value for the company's overall valuation and market capitalisation.
Genfit S.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
Genfit S.A.'s total assets of $216.68 Million consist of 61.3% current assets and 38.7% non-current assets. Review GNFT total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 54.0% |
| Accounts Receivable | $7.56 Million | 5.0% |
| Inventory | $4.00K | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $48.00 Million | 31.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how Genfit S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See GNFT live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genfit S.A.'s current assets represent 61.3% of total assets in 2024, an increase from 54.8% in 2004.
- Cash Position: Cash and equivalents constituted 54.0% of total assets in 2024, up from 1.9% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 31.7% of total assets.
Genfit S.A. Competitors by Total Assets
Key competitors of Genfit S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Genfit S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.74 | 3.74 | 5.71 |
| Quick Ratio | 3.74 | 3.74 | 5.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $113.85 Million | $99.95 Million | $196.50 Million |
Genfit S.A. - Advanced Valuation Insights
This section examines the relationship between Genfit S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.89 |
| Latest Market Cap to Assets Ratio | 1.61 |
| Asset Growth Rate (YoY) | -12.9% |
| Total Assets | $151.42 Million |
| Market Capitalization | $244.43 Million USD |
Valuation Analysis
Above Book Valuation: The market values Genfit S.A.'s assets above their book value (1.61x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Genfit S.A.'s assets decreased by 12.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genfit S.A. (2004–2024)
The table below shows the annual total assets of Genfit S.A. from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $151.42 Million | -12.91% |
| 2023-12-31 | $173.87 Million | -19.33% |
| 2022-12-31 | $215.54 Million | -23.49% |
| 2021-12-31 | $281.72 Million | +41.84% |
| 2020-12-31 | $198.61 Million | -35.90% |
| 2019-12-31 | $309.85 Million | +35.03% |
| 2018-12-31 | $229.48 Million | -21.73% |
| 2017-12-31 | $293.18 Million | +76.39% |
| 2016-12-31 | $166.21 Million | +139.99% |
| 2015-12-31 | $69.26 Million | -19.81% |
| 2014-12-31 | $86.37 Million | +196.27% |
| 2013-12-31 | $29.15 Million | +23.62% |
| 2012-12-31 | $23.58 Million | -18.90% |
| 2011-12-31 | $29.08 Million | -7.36% |
| 2010-12-31 | $31.39 Million | -18.32% |
| 2009-12-31 | $38.43 Million | -16.45% |
| 2008-12-31 | $45.99 Million | +14.37% |
| 2007-12-31 | $40.21 Million | -13.04% |
| 2006-12-31 | $46.24 Million | +49.98% |
| 2005-12-31 | $30.83 Million | +0.75% |
| 2004-12-31 | $30.61 Million | -- |
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more